The current financial score of Novo Nordisk A/S is 8.95. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 12.19B, representing a year-over-year increase of 3.80%, while its net profit experienced a year-over-year increase of 17.77%.
The current valuation score of Novo Nordisk A/S is 8.74. Its current P/E ratio is 9.73, which is 419.61% below the recent high of 50.57 and 10.29% above the recent low of 8.73.
The current earnings forecast score of Novo Nordisk A/S is 6.31. The average price target is 48.19, with a high of 65.00 and a low of 40.00.
The current price momentum score of Novo Nordisk A/S is 4.17. Currently, the stock price is trading between the resistance level at 43.91 and the support level at 38.63, making it suitable for range-bound swing trading.
The current institutional shareholding score of Novo Nordisk A/S is 3.00. The latest institutional shareholding proportion is 9.89%, representing a quarter-over-quarter increase of 7.16%.
The current risk assessment score of Novo Nordisk A/S is 6.62. The company's beta value is 0.79. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.